Amgen receives positive CHMP opinion for broader Repatha use
The opinion supports use before first heart attack or stroke, based on VESALIUS-CV trial results.
See the latest news and media coverage for Amgen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multinational biopharmaceutical company
amgen.comLast updated
In short: Amgen expanded its cardiovascular and oncology portfolios while navigating drug safety concerns in Japan and ongoing federal tax litigation.
The opinion supports use before first heart attack or stroke, based on VESALIUS-CV trial results.
The collaboration funds a new Stand Up To Cancer Pediatric Cancer Dream Team and a global awareness campaign.
The call will take place on August 4, 2026, at 1:30 PM PDT with a webcast option.
Repatha reduced cardiovascular events by 29% in high-risk diabetes patients. Real-world data highlight treatment gaps.
Amgen stock trades steadily on Nasdaq as fresh obesity trial data and consistent quarterly earnings with rising Repatha and Otezla sales underpin the biotech group’s...
Drugmaker Amgen said on Friday hackers stole company data and patient health information in a cyber...
Amgen (NasdaqGS:AMGN) received a positive opinion from the European Medicines Agency's CHMP for an expanded Repatha indication in Europe. The recommendation covers use of Repatha...
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the...
Track Amgen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Amgen and other trending companies.